Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Common Equity (2020 - 2026)

RxSight filings provide 6 years of Common Equity readings, the most recent being $275.7 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 1.98% to $275.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $275.7 million, a 1.98% decrease, with the full-year FY2025 number at $275.7 million, down 1.98% from a year prior.
  • Common Equity hit $275.7 million in Q4 2025 for RxSight, roughly flat from $276.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $281.2 million in Q4 2024 to a low of -$313.4 million in Q2 2021.
  • Median Common Equity over the past 5 years was $158.8 million (2023), compared with a mean of $141.2 million.
  • The widest YoY moves for Common Equity: up 140.8% in 2022, down 36.41% in 2022.
  • RxSight's Common Equity stood at $138.2 million in 2021, then tumbled by 34.97% to $89.9 million in 2022, then soared by 78.37% to $160.4 million in 2023, then soared by 75.38% to $281.2 million in 2024, then fell by 1.98% to $275.7 million in 2025.
  • The last three reported values for Common Equity were $275.7 million (Q4 2025), $276.0 million (Q3 2025), and $278.0 million (Q2 2025) per Business Quant data.